Experts discuss the evolving role of checkpoint inhibition in patients with advanced bladder cancer.
This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with bladder cancer.
The goal of this activity is to discuss the role of immunotherapy, including how to determine eligibility and how to manage immune-related adverse events (irAEs), in the treatment of advanced bladder cancer.
Approximate Time to Complete: 30 minutes
Credit Available: Apr. 30, 2019- Apr. 30, 2020
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding Clinical trial data on the use of immune checkpoint inhibitors in patients with bladder cancer
- Have greater competence related to selecting the most appropriate regimen for patients with advanced bladder cancer
- Have greater competence related to managing immune-related adverse events